Published in J Biol Chem on March 05, 2012
THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY. Biochem J (1963) 61.56
Complement: a key system for immune surveillance and homeostasis. Nat Immunol (2010) 10.37
Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A (1976) 6.65
Biosynthesis of the complement components and the regulatory proteins of the alternative complement pathway by human peripheral blood monocytes. J Exp Med (1980) 3.50
Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b. J Exp Med (1986) 2.94
Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator. Proc Natl Acad Sci U S A (1979) 2.73
Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet (2004) 2.55
Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat Immunol (2009) 2.54
Complement activation and inhibition: a delicate balance. Trends Immunol (2009) 2.22
Purification of C3b inactivator and demonstration of its two polypeptide chain structure. J Immunol (1977) 2.16
Ultrastructures and interactions of complement factors H and I. J Immunol (1992) 1.49
Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol (2007) 1.42
Characterization of primary amino acid sequence of human complement control protein factor I from an analysis of cDNA clones. Biochem J (1987) 1.32
CCP1-4 of the C4b-binding protein alpha-chain are required for factor I mediated cleavage of complement factor C3b. Mol Immunol (2003) 1.32
Control of the function of substrate-bound C4b-C3b by the complement receptor Cr1. J Exp Med (1984) 1.23
A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. Mol Immunol (2006) 1.15
Structural basis for complement factor I control and its disease-associated sequence polymorphisms. Proc Natl Acad Sci U S A (2011) 1.12
Complement factor I in health and disease. Mol Immunol (2011) 1.10
Biosynthesis and postsynthetic processing of human C3b/C4b inactivator (factor I) in three hepatoma cell lines. J Biol Chem (1984) 1.07
Inhibition of factor I by diisopropylfluorophosphate. Evidence of conformational changes in factor I induced by C3b and additional studies on the specificity of factor I. J Immunol (1990) 1.04
Genetic, molecular and functional analyses of complement factor I deficiency. Eur J Immunol (2009) 1.04
Inhibition of platelet prothrombinase activity by a lupus anticoagulant. Blood (1983) 1.02
Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. Mol Immunol (2007) 1.02
Functional activity of the complement regulator encoded by Kaposi's sarcoma-associated herpesvirus. J Biol Chem (2003) 1.02
Complement diversity: a mechanism for generating immune diversity? Immunol Today (1998) 1.00
Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor I. Eur J Immunol (2010) 0.95
In vitro biosynthesis of complement factor I by human endothelial cells. Eur J Immunol (1992) 0.92
Human complement factor I glycosylation: structural and functional characterisation of the N-linked oligosaccharides. Biochim Biophys Acta (2006) 0.91
Human complement factor I does not require cofactors for cleavage of synthetic substrates. J Immunol (2004) 0.90
The molecular basis of hereditary complement factor I deficiency. J Clin Invest (1996) 0.88
Molecular modelling of the domain structure of factor I of human complement by X-ray and neutron solution scattering. Biochem J (1993) 0.88
Human keratinocytes produce the complement inhibitor factor I: Synthesis is regulated by interferon-gamma. Mol Immunol (2007) 0.83
Analysis of binding sites on complement factor I that are required for its activity. J Biol Chem (2009) 0.82
Secreted frizzled-related protein 4 reduces insulin secretion and is overexpressed in type 2 diabetes. Cell Metab (2012) 2.46
Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J Immunol (2012) 2.12
C4b-binding protein (C4BP) activates B cells through the CD40 receptor. Immunity (2003) 2.04
Complement inhibitor C4b-binding protein-friend or foe in the innate immune system? Mol Immunol (2004) 1.61
Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol (2011) 1.61
The extracellular matrix and inflammation: fibromodulin activates the classical pathway of complement by directly binding C1q. J Biol Chem (2005) 1.61
FAF-Drugs2: free ADME/tox filtering tool to assist drug discovery and chemical biology projects. BMC Bioinformatics (2008) 1.60
The anticoagulant protein C pathway. FEBS Lett (2005) 1.56
Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int (2009) 1.55
The factor H variant associated with age-related macular degeneration (His-384) and the non-disease-associated form bind differentially to C-reactive protein, fibromodulin, DNA, and necrotic cells. J Biol Chem (2007) 1.51
Biphasic effect of gingipains from Porphyromonas gingivalis on the human complement system. J Immunol (2007) 1.50
A novel interaction of outer membrane protein A with C4b binding protein mediates serum resistance of Escherichia coli K1. J Immunol (2002) 1.47
Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition. Arterioscler Thromb Vasc Biol (2005) 1.46
Binding of flavivirus nonstructural protein NS1 to C4b binding protein modulates complement activation. J Immunol (2011) 1.45
Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke. Thromb Res (2003) 1.44
Rheumatoid arthritis and the complement system. Ann Med (2007) 1.42
Binding of the complement inhibitor C4bp to serogroup B Neisseria meningitidis. J Immunol (2005) 1.38
Yersinia enterocolitica serum resistance proteins YadA and ail bind the complement regulator C4b-binding protein. PLoS Pathog (2008) 1.36
Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery. Drug Discov Today (2010) 1.33
The emerging pathogen Moraxella catarrhalis interacts with complement inhibitor C4b binding protein through ubiquitous surface proteins A1 and A2. J Immunol (2004) 1.32
A formylated hexapeptide ligand mimics the ability of Wnt-5a to impair migration of human breast epithelial cells. J Biol Chem (2005) 1.32
Endoglycosidase treatment abrogates IgG arthritogenicity: importance of IgG glycosylation in arthritis. Eur J Immunol (2007) 1.32
Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest (2004) 1.31
C4b-binding protein and factor H compensate for the loss of membrane-bound complement inhibitors to protect apoptotic cells against excessive complement attack. J Biol Chem (2007) 1.30
A functional variant in the CFI gene confers a high risk of age-related macular degeneration. Nat Genet (2013) 1.29
FAF-Drugs: free ADME/tox filtering of compound collections. Nucleic Acids Res (2006) 1.29
Rationalizing the chemical space of protein-protein interaction inhibitors. Drug Discov Today (2009) 1.27
Designing focused chemical libraries enriched in protein-protein interaction inhibitors using machine-learning methods. PLoS Comput Biol (2010) 1.24
Regulation of complement by cartilage oligomeric matrix protein allows for a novel molecular diagnostic principle in rheumatoid arthritis. Arthritis Rheum (2010) 1.23
Fast structure-based virtual ligand screening combining FRED, DOCK, and Surflex. J Med Chem (2005) 1.22
Short leucine-rich glycoproteins of the extracellular matrix display diverse patterns of complement interaction and activation. Mol Immunol (2008) 1.21
Human C4b-binding protein selectively interacts with Neisseria gonorrhoeae and results in species-specific infection. Proc Natl Acad Sci U S A (2005) 1.20
Clinical isolates of Streptococcus pneumoniae bind the complement inhibitor C4b-binding protein in a PspC allele-dependent fashion. J Immunol (2009) 1.18
Nontypeable Haemophilus influenzae protein E binds vitronectin and is important for serum resistance. J Immunol (2009) 1.17
Interpain A, a cysteine proteinase from Prevotella intermedia, inhibits complement by degrading complement factor C3. PLoS Pathog (2009) 1.16
Inhibition of coxsackie B virus infection by soluble forms of its receptors: binding affinities, altered particle formation, and competition with cellular receptors. J Virol (2005) 1.15
A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. Mol Immunol (2006) 1.15
Binding of complement inhibitor C4b-binding protein contributes to serum resistance of Porphyromonas gingivalis. J Immunol (2008) 1.14
Scabies mite inactivated serine protease paralogs inhibit the human complement system. J Immunol (2009) 1.11
PCE: web tools to compute protein continuum electrostatics. Nucleic Acids Res (2005) 1.11
Logarithmic phase Escherichia coli K1 efficiently avoids serum killing by promoting C4bp-mediated C3b and C4b degradation. Immunology (2006) 1.10
Vitamin K-dependent protein S localizing complement regulator C4b-binding protein to the surface of apoptotic cells. J Immunol (2002) 1.10
Complement factor I in health and disease. Mol Immunol (2011) 1.10
Toward in silico structure-based ADMET prediction in drug discovery. Drug Discov Today (2011) 1.10
The Kaposi's sarcoma-associated herpesvirus complement control protein (KCP) binds to heparin and cell surfaces via positively charged amino acids in CCP1-2. Mol Immunol (2006) 1.08
beta-Microseminoprotein binds CRISP-3 in human seminal plasma. Biochem Biophys Res Commun (2005) 1.07
A metalloproteinase karilysin present in the majority of Tannerella forsythia isolates inhibits all pathways of the complement system. J Immunol (2012) 1.07
MS-DOCK: accurate multiple conformation generator and rigid docking protocol for multi-step virtual ligand screening. BMC Bioinformatics (2008) 1.07
Effects of complement regulators bound to Escherichia coli K1 and Group B Streptococcus on the interaction with host cells. Immunology (2007) 1.05
Regulation of complement activation by C-reactive protein: targeting of the inhibitory activity of C4b-binding protein. J Immunol (2006) 1.05
Receptor-based computational screening of compound databases: the main docking-scoring engines. Curr Protein Pept Sci (2006) 1.04
Genetic, molecular and functional analyses of complement factor I deficiency. Eur J Immunol (2009) 1.04
Defining targets for complement components C4b and C3b on the pathogenic neisseriae. Infect Immun (2007) 1.03
Identification of a catalytic exosite for complement component C4 on the serine protease domain of C1s. J Immunol (2012) 1.03
Complement inhibitor C4b-binding protein interacts directly with small glycoproteins of the extracellular matrix. J Immunol (2009) 1.03
A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity. J Immunol (2008) 1.03
Enolase of Streptococcus pneumoniae binds human complement inhibitor C4b-binding protein and contributes to complement evasion. J Immunol (2012) 1.02
Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. Mol Immunol (2007) 1.02
Staphylococcal proteases aid in evasion of the human complement system. J Innate Immun (2013) 1.02
Functional activity of the complement regulator encoded by Kaposi's sarcoma-associated herpesvirus. J Biol Chem (2003) 1.02
Novel scabies mite serpins inhibit the three pathways of the human complement system. PLoS One (2012) 1.02
The gamma-carboxyglutamic acid domain of anticoagulant protein S is involved in activated protein C cofactor activity, independently of phospholipid binding. Blood (2004) 1.01
iPPI-DB: a manually curated and interactive database of small non-peptide inhibitors of protein-protein interactions. Drug Discov Today (2013) 1.01
The C4b-binding protein-protein S complex inhibits the phagocytosis of apoptotic cells. J Biol Chem (2004) 1.00
The FAF-Drugs2 server: a multistep engine to prepare electronic chemical compound collections. Bioinformatics (2011) 1.00
How to choose relevant multiple receptor conformations for virtual screening: a test case of Cdk2 and normal mode analysis. Eur Biophys J (2010) 0.99
AMMOS: Automated Molecular Mechanics Optimization tool for in silico Screening. BMC Bioinformatics (2008) 0.99
Interaction with C4b-binding protein contributes to nontypeable Haemophilus influenzae serum resistance. J Immunol (2007) 0.99
Streptococcus pneumoniae endopeptidase O (PepO) is a multifunctional plasminogen- and fibronectin-binding protein, facilitating evasion of innate immunity and invasion of host cells. J Biol Chem (2013) 0.98
Haemophilus influenzae protein E recognizes the C-terminal domain of vitronectin and modulates the membrane attack complex. Mol Microbiol (2011) 0.98
C4b-binding protein in Alzheimer's disease: binding to Abeta1-42 and to dead cells. Mol Immunol (2008) 0.97
Early complementopathy after multiple injuries in humans. Shock (2012) 0.97
Binding of the complement inhibitor C4b-binding protein to Lyme disease Borreliae. Mol Immunol (2009) 0.97
Ionic binding of C3 to the human pathogen Moraxella catarrhalis is a unique mechanism for combating innate immunity. J Immunol (2005) 0.97
Design of protein membrane interaction inhibitors by virtual ligand screening, proof of concept with the C2 domain of factor V. Proc Natl Acad Sci U S A (2007) 0.96
Haemophilus influenzae acquires vitronectin via the ubiquitous Protein F to subvert host innate immunity. Mol Microbiol (2013) 0.96
Structural requirements for the intracellular subunit polymerization of the complement inhibitor C4b-binding protein. Biochemistry (2002) 0.96
Human C4b-binding protein, structural basis for interaction with streptococcal M protein, a major bacterial virulence factor. J Biol Chem (2005) 0.96
Native, amyloid fibrils and beta-oligomers of the C-terminal domain of human prion protein display differential activation of complement and bind C1q, factor H and C4b-binding protein directly. Mol Immunol (2008) 0.95
Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor I. Eur J Immunol (2010) 0.95
Haemophilus influenzae interacts with the human complement inhibitor factor H. J Immunol (2008) 0.95
Vitronectin binds to the head region of Moraxella catarrhalis ubiquitous surface protein A2 and confers complement-inhibitory activity. Mol Microbiol (2010) 0.94
Receptor-based virtual ligand screening for the identification of novel CDC25 phosphatase inhibitors. J Chem Inf Model (2007) 0.94
MED-3DMC: a new tool to generate 3D conformation ensembles of small molecules with a Monte Carlo sampling of the conformational space. Eur J Med Chem (2008) 0.94
Degradation of neutrophil extracellular traps co-varies with disease activity in patients with systemic lupus erythematosus. Arthritis Res Ther (2013) 0.94
Heptose I glycan substitutions on Neisseria gonorrhoeae lipooligosaccharide influence C4b-binding protein binding and serum resistance. Infect Immun (2007) 0.94
Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96. Eur J Cancer (2012) 0.93
Proposed structural models of the prothrombinase (FXa-FVa) complex. Proteins (2006) 0.93
Haemophilus influenzae protein E binds to the extracellular matrix by concurrently interacting with laminin and vitronectin. J Infect Dis (2011) 0.93
UPF2 is a critical regulator of liver development, function and regeneration. PLoS One (2010) 0.93
Serglycin is implicated in the promotion of aggressive phenotype of breast cancer cells. PLoS One (2013) 0.92